Growth factors in bone marrow transplant recipients
- PMID: 3067778
Growth factors in bone marrow transplant recipients
Abstract
Normal human plasma samples usually support the growth of hemopoietic progenitors in the presence of exogenous growth factors. In contrast, plasma samples collected serially from bone marrow transplant recipients after administration of their preparative regimen demonstrate activities that routinely stimulate the growth of granulocyte-macrophage progenitors (CFU-GM) and precursors for megakaryocytes (CFU-Meg). The peak activities are usually observed between day 7 and day 21. Occasionally growth promoting activities for erythroid bursts are also observed. Activities for the growth of multilineage colonies are only rarely seen. These growth promoting activities for CFU-GM and CFU-Meg usually return to pretransplant values by day 30 in patients with prompt engraftment. Patients with delayed engraftment sustain high levels of growth promoting activities for long periods of time.
Similar articles
-
Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients.J Clin Invest. 1988 Jul;82(1):255-61. doi: 10.1172/JCI113579. J Clin Invest. 1988. PMID: 3292585 Free PMC article.
-
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.Exp Hematol. 1995 Dec;23(14):1520-6. Exp Hematol. 1995. PMID: 8542941
-
Synergistic effect of stem cell factor with interleukin-3 or granulocyte-macrophage colony-stimulating factor on the proliferation of murine primitive hematopoietic progenitors.Exp Hematol. 1994 Jun;22(6):495-500. Exp Hematol. 1994. PMID: 7514543
-
Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.Exp Hematol. 1993 Mar;21(3):405-410. Exp Hematol. 1993. PMID: 8440338
-
Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.Exp Hematol. 1995 Dec;23(14):1661-6. Exp Hematol. 1995. PMID: 8542962
MeSH terms
Substances
LinkOut - more resources
Medical